Mizuho Issues Positive Forecast for Cencora (NYSE:COR) Stock Price

Cencora (NYSE:COR) had its target price upped by Mizuho from $340.00 to $380.00 in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other equities research analysts have also recently commented on COR. Morgan Stanley set a $330.00 price objective on Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. UBS Group raised their price target on shares of Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a report on Monday, October 27th. Wells Fargo & Company lifted their price target on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, Evercore ISI set a $340.00 target price on shares of Cencora in a research report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $348.00.

Cencora Trading Up 1.8%

Shares of NYSE COR opened at $360.29 on Thursday. The firm’s 50 day moving average price is $312.89 and its 200-day moving average price is $298.79. Cencora has a 52-week low of $223.92 and a 52-week high of $362.00. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The company has a market cap of $69.85 billion, a PE ratio of 37.07, a P/E/G ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period in the previous year, the business earned $3.34 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts expect that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is presently 22.63%.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 41,544 shares of company stock valued at $12,230,941. 10.80% of the stock is owned by insiders.

Institutional Trading of Cencora

A number of institutional investors have recently bought and sold shares of COR. Cidel Asset Management Inc. grew its position in Cencora by 7.0% during the 3rd quarter. Cidel Asset Management Inc. now owns 930 shares of the company’s stock worth $291,000 after purchasing an additional 61 shares during the last quarter. CENTRAL TRUST Co lifted its stake in shares of Cencora by 116.0% during the third quarter. CENTRAL TRUST Co now owns 3,500 shares of the company’s stock worth $1,094,000 after buying an additional 1,880 shares during the period. Rothschild Capital Partners LLC purchased a new stake in shares of Cencora during the third quarter valued at $200,000. Longbow Finance SA acquired a new position in shares of Cencora in the 3rd quarter valued at $10,553,000. Finally, Metis Global Partners LLC raised its stake in Cencora by 7.7% in the 3rd quarter. Metis Global Partners LLC now owns 9,208 shares of the company’s stock worth $2,878,000 after acquiring an additional 661 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.